Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02282761 · ClinicalTrials.gov registry record · Phase 3
A Trial to Assess the Antipsychotic Efficacy of ITI-007
A Phase 3 study, sponsored by Intra-Cellular Therapies.
- Completed
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
NCT02282761 is a Phase 3 study that has completed, run by Intra-Cellular Therapies. The registered enrollment target is 450 participants.
The verdict
NCT02282761, a Phase 3 study, has completed, sponsored by Intra-Cellular Therapies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
Study Summary
The study will be conducted as a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.
Interventions
- DRUG Placebo
- DRUG ITI-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02282761
The ClinicalTrials.gov registry entry for NCT02282761 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intra-Cellular Therapies, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02282761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02282761 about?
NCT02282761 is a clinical study titled "A Trial to Assess the Antipsychotic Efficacy of ITI-007". The study will be conducted as a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.
What is the current status of trial NCT02282761?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2014-11. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02282761?
The interventions under investigation include: Placebo (DRUG), ITI-007 (DRUG).
Who is sponsoring clinical trial NCT02282761?
This trial is sponsored by Intra-Cellular Therapies, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.